These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22960998)

  • 1. The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent.
    Stringer F; Scott G; Valbuena M; Kinley J; Nishihara M; Urquhart R
    Eur J Clin Pharmacol; 2013 Mar; 69(3):423-30. PubMed ID: 22960998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar.
    Stringer F; Ploeger BA; DeJongh J; Scott G; Urquhart R; Karim A; Danhof M
    J Clin Pharmacol; 2013 Mar; 53(3):256-63. PubMed ID: 23444281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar.
    Stringer F; DeJongh J; Scott G; Danhof M
    J Clin Pharmacol; 2014 Apr; 54(4):453-61. PubMed ID: 24214217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UDP-glucuronosyltransferase 2B15 (UGT2B15) is the major enzyme responsible for sipoglitazar glucuronidation in humans: retrospective identification of the UGT isoform by in vitro analysis and the effect of UGT2B15*2 mutation.
    Nishihara M; Hiura Y; Kawaguchi N; Takahashi J; Asahi S
    Drug Metab Pharmacokinet; 2013; 28(6):475-84. PubMed ID: 23648677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion.
    He X; Hesse LM; Hazarika S; Masse G; Harmatz JS; Greenblatt DJ; Court MH
    Br J Clin Pharmacol; 2009 Nov; 68(5):721-30. PubMed ID: 19916996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.
    Naik H; Wu JT; Palmer R; McLean L
    Br J Clin Pharmacol; 2012 Aug; 74(2):327-35. PubMed ID: 22242967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.
    Stingl JC; Bartels H; Viviani R; Lehmann ML; Brockmöller J
    Pharmacol Ther; 2014 Jan; 141(1):92-116. PubMed ID: 24076267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic fate of sipoglitazar, a novel oral PPAR agonist with activities for PPAR-γ, -α and -δ, in rats and monkeys and comparison with humans in vitro.
    Nishihara M; Sudo M; Kamiguchi H; Kawaguchi N; Maeshiba Y; Kiyota Y; Takahashi J; Tagawa Y; Kondo T; Asahi S
    Drug Metab Pharmacokinet; 2012; 27(2):223-31. PubMed ID: 22123126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An unusual metabolic pathway of sipoglitazar, a novel antidiabetic agent: cytochrome P450-catalyzed oxidation of sipoglitazar acyl glucuronide.
    Nishihara M; Sudo M; Kawaguchi N; Takahashi J; Kiyota Y; Kondo T; Asahi S
    Drug Metab Dispos; 2012 Feb; 40(2):249-58. PubMed ID: 22028317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional UDP-glucuronyltransferase 2B15 polymorphism and bisphenol A concentrations in blood: results from physiologically based kinetic modelling.
    Partosch F; Mielke H; Gundert-Remy U
    Arch Toxicol; 2013 Jul; 87(7):1257-64. PubMed ID: 23404680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver.
    Court MH; Hao Q; Krishnaswamy S; Bekaii-Saab T; Al-Rohaimi A; von Moltke LL; Greenblatt DJ
    J Pharmacol Exp Ther; 2004 Aug; 310(2):656-65. PubMed ID: 15044558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables.
    Navarro SL; Chen Y; Li L; Li SS; Chang JL; Schwarz Y; King IB; Potter JD; Bigler J; Lampe JW
    Drug Metab Dispos; 2011 Sep; 39(9):1650-7. PubMed ID: 21666065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer.
    Park J; Chen L; Shade K; Lazarus P; Seigne J; Patterson S; Helal M; Pow-Sang J
    J Urol; 2004 Jun; 171(6 Pt 1):2484-8. PubMed ID: 15126881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers.
    Chung JY; Cho JY; Yu KS; Kim JR; Jung HR; Lim KS; Jang IJ; Shin SG
    Clin Pharmacol Ther; 2005 Jun; 77(6):486-94. PubMed ID: 15961980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.
    Lévesque E; Delage R; Benoit-Biancamano MO; Caron P; Bernard O; Couture F; Guillemette C
    Clin Pharmacol Ther; 2007 Mar; 81(3):392-400. PubMed ID: 17339869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphism of UDP-glucuronosyltransferase (UGT2B15) and glucuronidation of paracetamol in healthy population.
    Mehboob H; Iqbal T; Jamil A; Khaliq T
    Pak J Pharm Sci; 2016 May; 29(3 Suppl):1037-41. PubMed ID: 27383482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y).
    Lampe JW; Bigler J; Bush AC; Potter JD
    Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):329-33. PubMed ID: 10750673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
    Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG
    Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers.
    Miller AK; DiCicco RA; Freed MI
    Clin Ther; 2002 Jul; 24(7):1062-71. PubMed ID: 12182252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.